Authors
Latest:
Matthew Frank, MD, PhD, on Investigation CD22 CAR for LBCL After CD19 RelapseThe assistant professor of BMT and cellular therapy discussed updated safety and efficacy data on CD22 CAR T-cell therapy.
Latest:
Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma: Mansi R. Shah, MDThe hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.
Latest:
CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RNThe lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
Latest:
James Lim, PhD, on Addressing Lingering Needs in Research Process Development and Clinical ManufacturingThe cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.
Latest:
Arshad Khanani, MD, on Future Plans for anti-VEGF Gene Therapy 4D-150The director of clinical research at Sierra Eye Associates discussed 4D Molecular Therapeutics’ plans for 4D-150 in both wet AMD and diabetic macular edema.
Latest:
CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACPThe director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.
Latest:
Paul Stewart, PhD, on the Potential of Genetic Medicine Approaches in Squamous Cell Lung CancerThe assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.
Latest:
ASCT Utilization Rates in Mantle Cell Lymphoma: Yazeed Sawalha, MDThe hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.
Latest:
Gerhard Ehninger, MD, on Managing Toxicities With Switchable CARs in AMLThe professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.
Latest:
Matt Angel, PhD, on Addressing Unmet Needs in Acute Myeloid Leukemia and Solid TumorsThe chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.
Latest:
Combining RNA and CAR T-Cell Therapy for Myasthenia GravisMichael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.
Latest:
Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCLClosing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
Latest:
Adham Bear, MD, On Immunotherapy Targeting Mutant KRASThe instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
Latest:
Harikrishna Nakshastri, PhD, on Characterizing Early Oncogenesis in Breast CancerThe professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.
Latest:
Susan Foy, PhD, on Evaluating Personalized, Neoantigen-Specific T Cell Therapy in Solid TumorsThe CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Latest:
Susie Long, PharmD, on ASTCT’s 2023 Fundamentals of HCT Training CourseThe pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.
Latest:
Cell Therapy for Dry AMD and Beyond: Next StepsLineage Cell Therapeutics CEO Brian Culley shares a clinical trial update on their leading cell therapy candidate and discusses the important role of the FDA as more players enter the cell and gene therapy space.
Latest:
Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T TherapiesThe associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.
Latest:
Looking Forward in Relapsed/Refractory Multiple Myeloma TreatmentsJames Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic ControllersThe chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.
Latest:
Developing Gene Therapies for Indications With Unmet NeedsThe chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
Latest:
Robert J. Hopkin, MD, on Assessing ST-920 for Fabry DiseaseThe associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center discussed Sangamo Therapeutics’ gene therapy, ST-920, and the phase 2 STAAR clinical trial.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Michael Leek, PhD, on Manufacturing Challenges in Cell TherapyThe co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
Latest:
Mathula Thangarajh, MD, PhD, on the Potential of Gene Therapy to Address Cognitive Symptoms in Muscular DystrophyThe child neurologist and neuromuscular physician at Virginia Commonwealth University also discussed the session she chaired at the 2023 MDA Clinical and Scientific Conference.
Latest:
Future Research With Stem Cell Therapies in Hematologic MalignanciesThe chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.
Latest:
Improving Access to Rare Disease CarePam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access to advanced care.
Latest:
Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MDThe assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.
Latest:
Selecting AAV Manufacturing PlatformsThe chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.
Latest:
Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade GliomaThe chief scientific officer at Candel Therapeutics discussed late-breaking data presented at ASGCT 2023.
